CD274 and non-small cell lung carcinoma: In addition to acting as a predictive biomarker for treatment response, PD-L1 could also be useful as a biomarker of prognosis, although, data regarding PD-L1 as a biomarker of prognosis is less consistent since studies investigating the prognostic role of PD-L1 and its association with clinicopathological features and driver mutations in NSCLC have yielded different results [14], thereby complicating the elaboration of conclusions about PD-L1 as a biomarker of prognosis.